Cardiovascular Benefits of Semaglutide in Non-Diabetic Patients

Evidence for Cardiovascular Risk Reduction

• The European Society of Cardiology recommends semaglutide for weight reduction in patients who don't reach weight targets through lifestyle modifications, based on evidence showing a 20% reduction in major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) with weekly subcutaneous semaglutide 2.4 mg compared to placebo (HR 0.80; 95% CI, 0.72-0.90; P<0.001) in patients with pre-existing cardiovascular disease who were overweight or obese but without diabetes 1
• The American Heart Association acknowledges that semaglutide produced sustained weight loss in patients with cardiovascular disease and obesity/overweight without diabetes, with mean reductions of 10.2% in body weight, 7.7 cm in waist circumference, and 6.9% in waist-to-height ratio at 208 weeks compared to minimal changes with placebo, as supported by the 2024 ESC guidelines for chronic coronary syndromes 1